PBAC's latest decision on Fosaprepitant: Recommended (2016). Considered for Prevention of nausea and vomiting associated with cytotoxic chemotherapy. Indicated for primary prophylaxis prior to highly emetogenic chemotherapy (HEC) or breast cancer chemotherapy with cyclophosphamide and anthracycline, secondary prophylaxis prior to moderately emetogenic chemotherapy (MEC), and primary prophylaxis prior to carboplatin/oxaliplatin regimens.
PBAC outcome
Recommended
Authority Required
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
1
first 2016
Submissions
1
2016 → 2016
Eligible population
Adult patients and children requiring prevention of nausea and vomiting associated with cytotoxic chemotherapy (highly emetogenic, moderately emetogenic, or carboplatin/oxaliplatin regimens), including those with difficulty swallowing or absorbing oral formulations.
Risk-sharing arrangement in place — Fosaprepitant included in existing aprepitant Risk Sharing Arrangement for use with carboplatin/oxaliplatin regimens from the first chemotherapy cycle without prior episode of CINV, with no change to existing caps.